Related Experiment Video

Updated: Jul 18, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Activated checkpoint kinase 2 provides a survival signal for tumor cells

Jagadish C Ghosh1, Takehiko Dohi, Christopher M Raskett

  • 1Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.

Cancer Research
|December 21, 2006
PubMed

Insights

Tumor cells resist DNA damage therapy by releasing survivin, an anti-apoptotic protein, via activated checkpoint kinase 2 (Chk2). Targeting Chk2 enhances tumor cell death and inhibits resistant tumor growth, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Tumor cells frequently develop resistance to DNA damage-based therapies.
  • The mechanisms underlying this therapeutic resistance remain largely unknown.
  • Understanding these mechanisms is crucial for developing more effective cancer treatments.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which tumor cells evade DNA damage-induced apoptosis.
  • To investigate the role of checkpoint kinase 2 (Chk2) in survivin regulation and chemoresistance.
  • To evaluate the therapeutic potential of targeting Chk2 in resistant tumors.

Main Methods:

  • Analysis of survivin localization in tumor cells following DNA damage.
  • Assessment of Chk2 activation and its interaction with survivin.
  • Inhibition of Chk2 activity using molecular or genetic approaches.
  • Evaluation of tumor cell apoptosis and in vivo tumor growth in response to Chk2 inhibition.

Main Results:

  • Tumor cells exposed to DNA damage release the anti-apoptotic protein survivin from mitochondria to prevent cell death.
  • This process is dependent on activated checkpoint kinase 2 (Chk2) and independent of p53.
  • Targeting Chk2 blocks survivin release, increases apoptosis, and reduces tumor growth in resistant models.
  • Activated Chk2 paradoxically promotes tumor cell survival, counteracting its tumor-suppressive role.

Conclusions:

  • Activated Chk2 promotes tumor cell survival by facilitating survivin release from mitochondria, contributing to therapy resistance.
  • Inhibiting Chk2 in combination with DNA-damaging agents represents a promising strategy for overcoming chemoresistance in tumors.
  • Targeting the Chk2-survivin axis offers a novel therapeutic avenue for treating resistant cancers.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...